Arbutus Biopharma Stock News

Arbutus Biopharma Corp (NASDAQ: ABUS) shares are trading higher after the company announced it received a $40M upfront payment from Qilu to commercialize AB-729 in Asia. William Collier, President a

Got $5 to spend on penny stocks? Take a look at these four for your watchlist The post Got $5 to Spend on Penny Stocks?

NEW YORK , Dec. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LCID, ET, ARDX, IINN, and ABUS. Full story available on Benzinga.com

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Eye-popping stocks: Arbutus Biopharma Corporation (NASDAQ:ABUS 4.11%), CVS Health Corporation (NYSE:CVS 4.52%) appeared first on Stocks Equity .

Arbutus Biopharma Co. (NASDAQ:ABUS) shares were up 4.6% during mid-day trading on Thursday . The stock traded as high as $4.42 and last traded at $4.33. Approximately 48,112 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 3,942,938 shares. The stock had previously closed at $4.14. A number []

Are these Reddit penny stocks on your watchlist right now? The post 4 Penny Stocks That Are Trending on Reddit Right Now and Why appeared first on Penny Stocks to Buy, Picks, News and Information | Pe

Brokerages predict that Arbutus Biopharma Co. (NASDAQ:ABUS) will post earnings of ($0.18) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Arbutus Biopharmas earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.19). Arbutus Biopharma posted earnings per share []

Analysts are bullish on these penny stocks in 2021. Should you be?

Arbutus Biopharma Corporation (NASDAQ: ABUS ) has identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease (Mpro), a validated target for treating COVID-19 and potential future coronavirus outbreaks. In April 2021, Arbutus, X-Chem Inc , and Proteros biostructures GmbH entered a discovery Full story available on Benzinga.com

The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) increased by over 10% during intraday trading today. This is why it happened.

Screening identifies several unique compound series that inhibit the SARS-CoV-2 nsp5 main protease, a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks

Arbutus Biopharma Corporation (NASDAQ: ABUS) has identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease (Mpro), a validated target for treating COVID-19 and potential future co

In the last trading session, 18.04 million Arbutus Biopharma Corporation (NASDAQ:ABUS) shares changed hands as the company’s beta touched 2.60. With the company’s per share price at $4.15 changed hands at -$0.16 or -3.71% during last session, the market valuation stood at $582.99M. ABUS’s last price was a discount, traded about -56.63% off its 52-week … Arbutus Biopharma Corporation (NASDAQ: ABUS) Is Expected To Soar To Higher Prices In The Months To Come. Read More »

Arbutus Biopharma (NASDAQ:ABUS) had its price target raised by Chardan Capital from $5.00 to $5.50 in a research note published on Thursday morning, The Fly reports. Chardan Capital currently has a buy rating on the biopharmaceutical companys stock. Other research analysts have also recently issued reports about the company. HC Wainwright cut their price target [] The post Arbutus Biopharma (NASDAQ:ABUS) Price Target Raised to $5.50 at Chardan Capital appeared first on ETF Daily News .